Date published: 2026-4-1

1-800-457-3801

SCBT Portrait Logo
Seach Input

Huntingtin Inhibitors

Huntingtin inhibitors represent a class of chemical compounds designed to target and modulate the activity of the huntingtin protein, a key player in the pathogenesis of Huntington's disease (HD). Huntington's disease is a devastating neurodegenerative disorder characterized by progressive motor dysfunction and cognitive impairment. The disease is primarily caused by a mutation in the HTT gene, which results in the production of a mutant huntingtin protein with an expanded polyglutamine tract. This mutant protein forms toxic aggregates in neurons, leading to neuronal dysfunction and death. Huntingtin inhibitors are developed with the aim of mitigating the pathological effects of mutant huntingtin in HD. These inhibitors primarily target various aspects of huntingtin biology, including its expression, post-translational modifications, and interactions with other cellular components. One approach involves small molecules that reduce the production of mutant huntingtin by inhibiting the translation of the HTT mRNA or enhancing its degradation. Another strategy focuses on preventing the abnormal aggregation of mutant huntingtin, either by directly disrupting the aggregation process or by promoting the clearance of existing aggregates through autophagy or other cellular mechanisms. Additionally, some huntingtin inhibitors aim to modulate the interactions between mutant huntingtin and its binding partners, altering its cellular effects.

Items 1 to 10 of 11 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Polyglutamine Aggregation Inhibitor, PGL-137

943-04-4sc-204208
10 mg
$184.00
(0)

PGL-137 is a specialized compound that targets polyglutamine aggregates, particularly those associated with huntingtin proteins. It engages in specific molecular interactions that stabilize misfolded proteins, preventing their aggregation. The compound exhibits unique binding kinetics, characterized by a high affinity for polyglutamine stretches, which alters the aggregation pathway. Its distinct structural features enhance solubility and promote favorable interactions with cellular chaperones, influencing protein homeostasis.

Polyglutamine Aggregation Inhibitor III, C2-8

300670-16-0sc-202766A
sc-202766B
sc-202766
sc-202766C
1 mg
5 mg
10 mg
25 mg
$47.00
$179.00
$312.00
$709.00
(0)

Polyglutamine Aggregation Inhibitor III, C2-8, is a novel compound that disrupts the formation of polyglutamine aggregates linked to huntingtin proteins. It operates through selective binding to the polyglutamine regions, effectively modulating the conformational dynamics of these proteins. The compound's unique structural motifs facilitate enhanced interaction with molecular chaperones, promoting a more favorable protein folding environment. Its kinetic profile suggests a rapid onset of action, influencing aggregation pathways and enhancing cellular resilience against misfolded proteins.

Quercetin

117-39-5sc-206089
sc-206089A
sc-206089E
sc-206089C
sc-206089D
sc-206089B
100 mg
500 mg
100 g
250 g
1 kg
25 g
$11.00
$17.00
$110.00
$250.00
$936.00
$50.00
33
(2)

Quercetin, a flavonoid found in many fruits and vegetables, has been studied for its potential to reduce the expression of mutant huntingtin protein and its associated toxic effects.

Curcumin

458-37-7sc-200509
sc-200509A
sc-200509B
sc-200509C
sc-200509D
sc-200509F
sc-200509E
1 g
5 g
25 g
100 g
250 g
1 kg
2.5 kg
$37.00
$69.00
$109.00
$218.00
$239.00
$879.00
$1968.00
47
(1)

Curcumin, the active compound in turmeric, has shown promise in reducing huntingtin protein aggregation, a hallmark of Huntington's disease.

(−)-Epigallocatechin Gallate

989-51-5sc-200802
sc-200802A
sc-200802B
sc-200802C
sc-200802D
sc-200802E
10 mg
50 mg
100 mg
500 mg
1 g
10 g
$43.00
$73.00
$126.00
$243.00
$530.00
$1259.00
11
(1)

(-)-Epigallocatechin Gallate, a major component of green tea, has been explored for its ability to modulate huntingtin protein expression and mitigate its toxic effects.

Sodium Butyrate

156-54-7sc-202341
sc-202341B
sc-202341A
sc-202341C
250 mg
5 g
25 g
500 g
$31.00
$47.00
$84.00
$222.00
19
(3)

Sodium butyrate, a short-chain fatty acid, has demonstrated potential in reducing huntingtin protein aggregation and improving cell survival.

Rapamycin

53123-88-9sc-3504
sc-3504A
sc-3504B
1 mg
5 mg
25 mg
$63.00
$158.00
$326.00
233
(4)

Rapamycin, an immunosuppressant, has been explored for its potential to decrease huntingtin protein aggregation and improve neuronal survival.

17-AAG

75747-14-7sc-200641
sc-200641A
1 mg
5 mg
$67.00
$156.00
16
(2)

17-AAG, a Hsp90 inhibitor, has demonstrated potential in reducing huntingtin protein levels and its associated neurodegenerative effects.

Salubrinal

405060-95-9sc-202332
sc-202332A
1 mg
5 mg
$34.00
$104.00
87
(2)

Salubrinal, a selective inhibitor of eIF2α dephosphorylation, has been studied for its potential to reduce huntingtin protein expression.

Caffeine

58-08-2sc-202514
sc-202514A
sc-202514B
sc-202514C
sc-202514D
50 g
100 g
250 g
1 kg
5 kg
$33.00
$67.00
$97.00
$192.00
$775.00
13
(1)

Caffeine has been explored for its neuroprotective properties and potential to decrease huntingtin protein aggregation.